|
|
| Product Name: | GSK840 | | Synonyms: | GSK840;tert-butyl 2-(4-(5-(methylcarbamoyl)-1H-benzo[d]imidazol-1-yl)phenyl)acetate;Inhibitor,RIP kinase,GSK 840,Receptor-interacting protein kinases,GSK840,inhibit,GSK-840,RIPK;tert-butyl2-(4-(5-(methylcarbamoyl)-1H-benzo[d]im;Benzeneacetic acid, 4-[5-[(methylamino)carbonyl]-1H-benzimidazol-1-yl]-, 1,1-dimethylethyl ester | | CAS: | 2361146-30-5 | | MF: | C21H23N3O3 | | MW: | 365.43 | | EINECS: | | | Product Categories: | | | Mol File: | 2361146-30-5.mol |  |
| | GSK840 Chemical Properties |
| density | 1.18±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | 110 mg/mL in DMSO | | form | Solid | | pka | 14.16±0.46(Predicted) | | color | Light yellow to yellow |
| | GSK840 Usage And Synthesis |
| Biological Activity | GSK840 is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, binds with high affinity to the RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM. | | in vitro | GSK840 (GSK'840) (0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in a concentration-dependent manner.
GSK840 binds the kinase domain and inhibits kinase activity with high specificity, targeting a broader range of pro-necrotic stimuli than can be achieved with RIP1 kinase inhibitors. Cell Viability Assay | Cell Line: | Human HT-29 cells (TNF 10 ng/ml + zVAD-fmk 20 μM + SMAC007 100 nM) | | Concentration: | 0.01-3 μM | | Incubation Time: | 24 hours | | Result: | Blocked TNF-induced necroptosis in a concentration-dependent manner. | | | target | |
| | GSK840 Preparation Products And Raw materials |
|